welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis
study id #: NCT00808743
condition: Familial Adenomatous Polyposis, Duodenal Neoplasms, Duodenal Polyps
Duodenal carcinomas are the leading cause of mortality in patients with Familial Adenomatous Polyposis (FAP) who underwent prophylactic colorectal surgery. The purpose of this study is to determine wether celecoxib combined with ursodeoxycholic acid is an effective chemoprevention strategy to influence the progression of duodenal adenomas to carcinomas in patients with FAP.
Drug: Ursodeoxycholic acid
start date: May 2009
estimated completion: January 2013
last updated: May 16, 2013
phase of development: Phase 2, Phase 3
size / enrollment: 37
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
- Change in number and size of duodenal adenomas (assessed directly and by evaluation of video and photographic material from endoscopic procedures) [ Time Frame:Baseline ] [ Designated as safety issue: No ]
- Cell proliferation, in normal mucosa and adenomas (if present) [ Time Frame: Baseline, 6 months ] [ Designated as safety issue: No ]
- Biliary acid profile (if present) [ Time Frame: Baseline, 6 months ] [ Designated as safety issue: No ]
- Patients with Familial adenomatous Polyposis: APC-mutation identified or more than 100 colorectal polyps on diagnosis
- Spigelman score of duodenal adenoma equal to II or III
- Incapability of signing informed consent
- Active gastric or duodenal ulcer, gastrointestinal bleeding
- Cardiovascular disease or risk:
- Congestive cardiac failure: NYHA class II to IV
- Proven ischemic heart disease and/or cerebrovascular disease
- Risk factors: hypertension, hyperlipidaemia, diabetes mellitus, family history of cardiovascular events (≥2 first degree family members <55 years)
- Renal dysfunction: creatinine clearance below 50mL/min
- Liver dysfunction: albumin below 25 g/L or Child-Pugh-score equal to or below 10
- Known allergic reaction to sulfonamides, NSAIDs or ursodeoxycholic acid
- Use of NSAIDs or ursodeoxycholic acid for more than 1 week during the 6 months prior to the start of the study
- Use of lithium
- Symptomatic gallstones
- Inflammatory bowel disease
- (Possible) pregnancy or breast feeding
expertly curated content related to this topic
Adenomatous Polyposis Syndromeshttps://www.youtube.com/watch?v=pFn-A2jZ...
Ostomy: Diet and Nutrition GuideThis guide provides some basic informati...
Familial Adenomatous Polyposis (FAP): InheritedFAP is an inherited colorectal cancer sy...
Familial Adenomatous Polyposis in Pediatrics: Natural History, Emerging Surveillance and Management Protocols, Chemo...Familial adenomatous polyposis (FAP) is ...
Chemoprevention of Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) has...
Precancerous Colorectal Lesions (Review)Colorectal cancer (CRC) is a common and ...
The Ileo Neo Rectal Anastomosis: Long-term Results of Surgical Innovation in Patients After Ulcerative Colitis and F...PURPOSE: Restorative proctocolectomy wi...